Indian Drug Makers Offer Deal To Avoid Increased Price Controls
This article was originally published in PharmAsia News
Drug makers in India are offering to sell some of their more important products at half of their maximum retail price to stave off greater price controls. But their offer is conditioned on the Indian government promising not to expand its cost-based price control policy. In addition to the half-off offer on some drugs, companies are offering to contribute a quarter of a percent of total profits to the government. An acceptance by the government would be considered a big change in the way India deals with the increasing cost of health care. (Click here for more
You may also be interested in...
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
Manufacturers warned to keep better electronic records and not falsify data in recent warning letters, ICH adds three residual solvent limits for pharmaceuticals, and the Polish authority hits firm for GMP noncompliance.